Loading...
Market
Type of Partnership for HRO761 Development by End of 2024
4
Resolution / Starting Odds
Pharmaceutical Company • 25%
Biotechnology Firm • 25%
Academic Institution • 25%
No new partnership • 25%
Press releases from NIBR, Vividion, or potential partners
Story
Breakthrough WRN Inhibitor HRO761 Targets MSI Cancers, Poised for Clinical Trials
Apr 24, 2024, 07:56 PM
Recent research has led to the discovery of a novel inhibitor, HRO761, targeting Werner Helicase (WRN), which shows synthetic lethality in microsatellite instability (MSI) cancers. This breakthrough, published in Nature, was achieved through chemoproteomic techniques that identified a covalent allosteric inhibitor of WRN. The research, spearheaded by NIBR and involving Vividion, marks a significant advancement in cancer treatment, particularly by transforming an ATP-competitive compound into an ATP-cooperative analogue. The development is poised for clinical testing to evaluate its effectiveness in human models of disease.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Moderna forms new partnerships • 25%
Pfizer/BioNTech forms new partnerships • 25%
Both companies form new partnerships • 25%
No new partnerships formed • 25%
None • 33%
1-2 new partnerships • 33%
More than 2 new partnerships • 33%
Pharmaceutical Company • 25%
Cancer Research Institution • 25%
University • 25%
Other Healthcare Provider • 25%
Yes • 50%
No • 50%
Partnership with Pfizer • 25%
Partnership with Johnson & Johnson • 25%
Partnership with Merck • 25%
No new partnership • 25%